Hepatitis B virus (HBV) RNA and HBcrAg (Hepatitis B core-related antigen) are both biomarkers that are used to assess disease activity in chronic hepatitis B (CHB) infection. These biomarkers can help in determining the criteria to cess NA therapy. According to the Japanese HBV guidance, the criteria to cess NA therapy are: At least 2 years of administration of NAs. Undetectable serum HBV DNA level. Negative serum HBeAg at the time of treatment cessation.
However, in case, when these criteria are met, HBsAg and HBcrAg levels can be used to estimate the risk of relapse at the time of cessation. Some of the additional points to note about HBcrAg in CHB management are:
Dr. Norah Terrault is an Director of Viral Hepatitis Research in Liver Transplantation. She has completed B.MSc. University of Alberta,1987 M.D. University of Alberta,1997 M.P.H. University of California, Berkeley.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details
Please login to comment on this article